Tower Research Capital LLC (Trc) Crinetics Pharmaceuticals, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 7,412 shares of CRNX stock, worth $265,201. This represents 0.01% of its overall portfolio holdings.
Number of Shares
7,412
Previous 452
1539.82%
Holding current value
$265,201
Previous $23,000
1543.48%
% of portfolio
0.01%
Previous 0.0%
Shares
24 transactions
Others Institutions Holding CRNX
# of Institutions
255Shares Held
89.5MCall Options Held
26.1KPut Options Held
11.8K-
Vanguard Group Inc Valley Forge, PA9.09MShares$325 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.95MShares$249 Million0.07% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$223 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$220 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$194 Million0.03% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.92B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...